Lobby advocates for venture capitalists, startups
This article was originally published in The Tan Sheet
Executive Summary
Frustrated by the lack of attention innovators and startups received during the health care reform debate, the National Venture Capital Association forms a group to speak up for the groups in national affairs. NVCA announced Sept. 7 its Medical Innovation and Competitiveness will push for more recognition for startups developing devices and therapeutics and the investors that back them. Kelly Slone, director of the NVCA's medical industry group, said, "No one is paying attention to these little companies and they're the ones really driving innovation." The coalition will push for a presidentially appointed position to assess the impact of new federal policies on medical innovation. With medical and biopharma startups already squeezed in capital markets, new uncertainties emerge from health care reform and a lack of predictability in the regulatory and reimbursement realms
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.